Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma.

Veerakumarasivam A, Goldstein LD, Saeb-Parsy K, Scott HE, Warren A, Thorne NP, Mills IG, Venkitaraman A, Neal DE, Kelly JD.

Cell Cycle. 2008 Nov 15;7(22):3525-33. Review.

PMID:
19001879
2.

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.

Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B.

J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11. doi: 10.1093/jnci/djn304. Erratum in: J Natl Cancer Inst. 2008 Dec 3;100(23):1740.

3.

Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells.

Chung CM, Man C, Jin Y, Jin C, Guan XY, Wang Q, Wan TS, Cheung AL, Tsao SW.

Mol Carcinog. 2005 Jul;43(3):165-74.

PMID:
15880741
4.

TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.

Sillars-Hardebol AH, Carvalho B, Tijssen M, Beliën JA, de Wit M, Delis-van Diemen PM, Pontén F, van de Wiel MA, Fijneman RJ, Meijer GA.

Gut. 2012 Nov;61(11):1568-75.

PMID:
22207630
5.

[Molecular changes in development and progression of urothelial carcinoma].

Hartmann A.

Verh Dtsch Ges Pathol. 2003;87:172-84. Review. German.

PMID:
16888910
6.

Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker.

Yen CC, Yeh CN, Cheng CT, Jung SM, Huang SC, Chang TW, Jan YY, Tzeng CH, Chao TC, Chen YY, Yang CY, Ho CL, Fletcher JA.

Ann Surg Oncol. 2012 Oct;19(11):3491-9. doi: 10.1245/s10434-012-2389-0.

PMID:
22588468
7.

Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.

Mohan P, Castellsague J, Jiang J, Allen K, Chen H, Nemirovsky O, Spyra M, Hu K, Kluwe L, Pujana MA, Villanueva A, Mautner VF, Keats JJ, Dunn SE, Lazaro C, Maxwell CA.

Oncotarget. 2013 Jan;4(1):80-93.

8.

Comprehensive genomic analysis identifies MDM2 and AURKA as novel amplified genes in juvenile angiofibromas.

Schick B, Wemmert S, Bechtel U, Nicolai P, Hofmann T, Golabek W, Urbschat S.

Head Neck. 2007 May;29(5):479-87.

PMID:
17120309
9.

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE.

Clin Cancer Res. 2013 Apr 1;19(7):1717-28. doi: 10.1158/1078-0432.CCR-12-2383.

10.

Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression.

Zhang C, Fang Z, Xiong Y, Li J, Liu L, Li M, Zhang W, Wan J.

Acta Biochim Biophys Sin (Shanghai). 2010 Nov;42(11):834-8. doi: 10.1093/abbs/gmq088.

PMID:
20929925
11.

Nupr1-aurora kinase A pathway provides protection against metabolic stress-mediated autophagic-associated cell death.

Hamidi T, Cano CE, Grasso D, Garcia MN, Sandi MJ, Calvo EL, Dagorn JC, Lomberk G, Urrutia R, Goruppi S, Carracedo A, Velasco G, Iovanna JL.

Clin Cancer Res. 2012 Oct 1;18(19):5234-46. doi: 10.1158/1078-0432.CCR-12-0026.

12.

Genetic instability persists in non-neoplastic urothelial cells from patients with a history of urothelial cell carcinoma.

de Castro Marcondes JP, de Oliveira ML, Gontijo AM, de Camargo JL, Salvadori DM.

PLoS One. 2014 Jan 22;9(1):e86162. doi: 10.1371/journal.pone.0086162.

13.

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.

Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072.

14.

A global profile of gene promoter methylation in treatment-naïve urothelial cancer.

Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG, Cairns P.

Epigenetics. 2014 May;9(5):760-73. doi: 10.4161/epi.28078.

15.

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.

Heubach J, Monsior J, Deenen R, Niegisch G, Szarvas T, Niedworok C, Schulz WA, Hoffmann MJ.

Mol Cancer. 2015 May 21;14:108. doi: 10.1186/s12943-015-0371-8.

16.

Centrosome amplification as a putative prognostic biomarker for the classification of urothelial carcinomas.

Yamamoto Y, Misumi T, Eguchi S, Chochi Y, Kitahara S, Nakao M, Nagao K, Hara T, Sakano S, Furuya T, Oga A, Kawauchi S, Sasaki K, Matsuyama H.

Hum Pathol. 2011 Dec;42(12):1923-30. doi: 10.1016/j.humpath.2011.02.013.

PMID:
21683985
17.

Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.

Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S.

Neoplasia. 2009 May;11(5):418-25.

18.

Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression.

Fang Z, Xiong Y, Li J, Liu L, Li M, Zhang C, Zhang W, Wan J.

Med Oncol. 2011 Dec;28(4):1017-22. doi: 10.1007/s12032-010-9602-4.

PMID:
20585902
19.

Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger.

Wild PJ, Giedl J, Stoehr R, Junker K, Boehm S, van Oers JM, Zwarthoff EC, Blaszyk H, Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI, Hartmann A.

J Pathol. 2007 Jan;211(1):18-25. Erratum in: J Pathol. 2012 Feb;226(3):e1.

PMID:
17072825
20.

Aurora-A gene is frequently amplified in basal-like breast cancer.

Staff S, Isola J, Jumppanen M, Tanner M.

Oncol Rep. 2010 Feb;23(2):307-12.

PMID:
20043089

Supplemental Content

Support Center